MINT-LOSARTAN TABLET

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

LOSARTAN POTASSIUM

זמין מ:

MINT PHARMACEUTICALS INC

קוד ATC:

C09CA01

INN (שם בינלאומי):

LOSARTAN

כמות:

50.0MG

טופס פרצבטיות:

TABLET

הרכב:

LOSARTAN POTASSIUM 50.0MG

מסלול נתינה (של תרופות):

ORAL

יחידות באריזה:

30/100/500

סוג מרשם:

Prescription

איזור תרפויטי:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

leaflet_short:

Active ingredient group (AIG) number: 0127971003; AHFS:

מצב אישור:

APPROVED

תאריך אישור:

2015-03-03

מאפייני מוצר

MINT-LOSARTAN
_MINT-LOSARTAN(losartan _
_potassium) _
_Page 1 of 44_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MINT-LOSARTAN
Losartan Potassium Tablets
Tablets, 25 mg, 50 mg and 100 mg, Oral
House Standard
Angiotensin II Receptor Antagonist
MINT PHARMACEUTICALS INC.
6575 Davand Drive
Mississauga, ON Canada L5T 2M3
Date of Initial Authorization:
May 9, 2013
Date of Revision:
April 18, 2023
Submission Control Number: 269236
_MINT-LOSARTAN_
_ _
_(losartan potassium) _
_Page 2 of 44_
_ _
RECENT MAJOR LABEL CHANGES
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................................
2
TABLE OF CONTENTS
...........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................................................
4
1
INDICATIONS
..........................................................................................................................
4
1.1
Pediatrics
..............................................................................................................................
4
1.2
Geriatrics
..............................................................................................................................
4
2
CONTRAINDICATIONS
.............................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.........................................................................
5
4
DOSAGE AND ADMINISTRATION
.............................................................................................
5
4.1
Dosing Considerations
..........................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
................